Conditions: Hepatitis C
Keywords: HCV genotype 2 (GT-2)
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 153
Healthy volunteers: no

Brief summary:
This study will evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (SOF) plus ribavirin (RBV) in Japanese participants with chronic genotype 2 hepatitis C virus (HCV) infection.

Detailed description:

Arms:
arm 1: Participants will receive sofosbuvir+RBV for 12 weeks.

Interventions: intervention 1: Sofosbuvir intervention 2: RBV
Intervention descriptions: intervention 1: Sofosbuvir 400 mg tablet administered orally once daily intervention 2: Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing according to the approved Copegus labeling in Japan (\< 60 kg = 600 mg , \> 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)

Protocol document: